昆藥集團(600422.SH):湘西華方土地及機器房屋擬被徵收及補償8000萬元
格隆匯1月15日丨昆藥集團(600422.SH)公佈,因湖南省吉首市人民政府為改善文峯樓片區居民居住環境,提升城市整體品質,公司全資子公司湘西華方製藥有限公司(以下簡稱“湘西華方”)位於吉首市乾州新區建新路168號公司國有出讓土地及國有土地上機器房屋進行徵收及補償,合計補償金額為税後8000萬元。
目前,湘西華方(以下簡稱“乙方”)與吉首市人民政府吉政發(2019)18號)文件中明確的徵收實施部門——吉首市房地產管理局(以下簡稱“甲方”)就上述土地、機器、房屋徵收與補償事宜商定了《吉首市國有土地上房屋徵收補償協議》及《吉首市國有土地上房屋徵收補償協議補充協議》,上述協議尚未簽訂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.